Exploring Genetic Predictors of GLP-1 Receptor Agonists with Dr. Adam Auton

Welcome back to the Docs Who Lift podcast! In this episode, Dr. Spencer Nadolsky and co-host Dr. Carl Nadolsky Jr. welcome special guest Dr. Adam Auton, a geneticist from 23andMe. Together, they discuss Dr. Auton’s recent research on genetic predictors of responses to GLP-1 receptor agonists, a class of medications that have transformed weight loss management.

Understanding GLP-1 Receptor Agonists

GLP-1 receptor agonists are medications that have significantly changed the landscape of weight loss and diabetes management. They have shown varied efficacy among individuals, with some experiencing remarkable weight loss and others facing unpleasant side effects. Dr. Auton’s research aims to uncover whether genetics plays a role in this variability.

The Research Background

Dr. Auton shares insights into the large database at 23andMe, which includes over 11 million customers who have opted to participate in research. The team launched a survey asking participants about their usage of GLP-1 medications, including dosage and reported side effects. This dataset enabled them to explore the genetic factors associated with the efficacy and side effects of these drugs.

Key Findings

Some significant discoveries from the study include:

• A specific genetic variant in the GLP-1 receptor correlates with medication efficacy, impacting how effectively the drug can perform its function.
• This same variant also appears to increase the likelihood of experiencing side effects like nausea and vomiting.
• Another genetic variant associated with the GIP receptor affects side effects related to tirzepatide, a medication that also targets this receptor.

Implications of Genetic Variability

Dr. Auton emphasizes that while genetics is a significant factor in medication response, it is not the sole determinant. Other factors such as sex, lifestyle, and adherence to medication play crucial roles in treatment outcomes. For instance, women generally respond better to GLP-1 medications compared to men. Understanding these genetic variations can help physicians better prepare patients for their treatment journeys.

Future Directions in Research

Looking ahead, the research team at 23andMe plans to explore additional questions regarding weight regain after discontinuation of GLP-1 medications and how genetic factors might influence this phenomenon. The ultimate goal is to move towards a more personalized approach to medicine, where genetic information can inform treatment plans.

Conclusion

Dr. Auton’s insights into the genetic predictors of GLP-1 receptor agonists provide a fascinating glimpse into the future of personalized medicine. As we learn more about the genetic factors influencing drug efficacy and side effects, we can better equip individuals on their weight loss and health journeys.

Key Takeaways

• GLP-1 receptor agonists show varied efficacy and side effects among individuals.
• Genetic variants in both the GLP-1 and GIP receptors play a role in medication response.
• Other factors, including lifestyle and gender, also significantly influence medication outcomes.
• Future research aims to explore genetic predictors of weight regain after medication cessation.